Skip to content
iSpecimen logo

iSpecimen

ISPC

iSpecimen Inc. operates a technology-driven global marketplace that connects life science researchers with healthcare providers to facilitate the procurement of human biospecimens and associated data.

Market cap
$2.89M-10.3%

Table of contents

Earnings

Next report

Aug 4, 2026 (In 6 days)

Competitors

Profile

iSpecimen Inc. operates a technology-driven global marketplace that connects life science researchers with healthcare providers to facilitate the procurement of human biospecimens and associated data. The platform automates the search, selection, and procurement process for biofluids, tissues, and living cells, aiming to accelerate medical discovery through a consolidated online experience.

Competitive position

iSpecimen maintains a unique position as a technology-based marketplace in a highly fragmented industry, though it faces significant competition from well-capitalized traditional biobanks and specimen providers.

GeographiesAmericas, Europe, Asia
Customer segmentsEnterprise, Public Sector, Academic
Business modelMarketplace, B2B, Data-as-a-Service
SuppliersHealthcare systems, Commercial laboratories, Blood centers, Biobanks, Cloud infrastructure providers (AWS, GCP, Azure)
CustomersDrug discovery researchers, Diagnostic product developers, Regenerative medicine researchers, Clinical trial sponsors
Listed2021
Employees53.0
CEOKatharyn Field
FilingsSEC EDGAR

Questions, answered.

What is iSpecimen's market cap?
iSpecimen (ISPC) has a market capitalization of $2.9M and trades on NASDAQ.
Who are iSpecimen's competitors?
iSpecimen's key competitors include Azenta, Thermo Fisher Scientific, Inc., BioLife Solutions Inc., and others. These companies compete in similar markets and product categories.
Who does iSpecimen partner with?
iSpecimen's notable partners include Centers for Disease Control and Prevention, FedEx, Amazon, and others.
Where is iSpecimen headquartered?
iSpecimen is headquartered in United States of America and employs approximately 53 people. It has been publicly traded since 2021.